Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article presents a dissenting opinion, arguing that the case described by Dr. Molina et al. was diffuse alopecia areata, not acute alopecia areata as claimed, emphasizing the importance of distinct clinical differences.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

In this study, researchers reported significantly higher serum calprotectin levels in alopecia areata patients compared to controls and that these levels were associated with the disease's severity, type, duration, and nail involvement, suggesting calprotectin as a potential marker for inflammation in these patients.

In this study, aralia continentalis extract was observed to promote hair follicle development in mice through anagen progression, with the low dose being more effective than the high dose.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

This study found that Atlantic croaker nuclear androgen receptors AR1 and AR2 have different binding affinities for androgens, suggesting that they may mediate distinct physiological actions in teleosts.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This case report describes a rare instance of sarcoidal granulomatous alopecia areata in a 42-year-old man, with histopathological findings suggesting inflammation but ruling out causes like tuberculosis and syphilis, resulting in treatment with tofacitinib.

This article discusses the broad traditional uses and potential pharmaceutical applications of burdock, recommending the development of new products but reporting no experimental findings.

This monograph reviews the diverse effects of algae metabolites on skin health in dermocosmetic applications, without presenting new experimental results, and highlights their potential benefits such as photoprotection and anti-aging.

This study found that their newly developed ADRL framework significantly improved the accuracy of scalp tissue layer segmentation in HR-MR images compared to existing methods.

This study found that in mice with alopecia areata, CD8+ T cells showed clonal expansion and specific regulatory networks, which might help identify new therapeutic targets for patients not responding to JAK inhibitors.

This study found that alginate beads containing monoolein demonstrated promising potential for managing wet wounds by better absorbing excess exudate and delivering adenosine locally, favoring drug localization in damaged porcine skin compared to an aqueous solution without affecting skin viability.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

This study reports that ritlecitinib 50 mg, with or without an initial loading dose, demonstrated meaningful and sustained efficacy up to 24 months in the Asian subpopulation with severe alopecia areata, showing significant scalp, eyebrow, and eyelash hair regrowth, along with an acceptable safety profile.

This study found that AR-007 degrades faster and has a stronger association with hsp70 than AR-014, suggesting it is less stable when bound to the androgen receptor.

Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This review discusses Amphiregulin (AREG) as a potential target for treating fibrotic disorders and cancer, highlighting its role in disease progression and promising results in preclinical studies and early trials.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.

This study found that the methanolic extract of Carthamus caeruleus roots significantly reduced inflammation, promoted wound healing, and enhanced hair growth in experimental models, supporting its traditional use in Northern Algeria as a skincare remedy.

This study explored the mechanism of Shaoyao Gancao decoction in treating alopecia areata and found that it may be closely related to the PI3K/AKT signaling pathway.